VBIO Stock Forecast: Valion Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.48
−11.02% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 2 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.0M
Ticker Nerd rank
2/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0−100.0% y/y
Operating income−$6.4M
Net income−$7.1M
Free cash flow−$5.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.2%
1M
−59.6%
YTD
−98.7%
1Y
−98.8%
From 52W high
−99.3%
From 52W low
0.0%
$0
$67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Valion Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
2/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
22
Revisions
20
Growth
10
Value
6
Accruals
5
Quality
4
Momentum
2
Issuance
1

Volatility (22): The share price has been relatively steady.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

VBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26VBIO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

VBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Valion Bio, Inc. returned −98.8% against +6.9% for the S&P 500, dividends included.

VBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
050100Jan 26Apr 26Jul 26Oct 26VBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.0×

Cheaper than 98% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−459.5%

Higher than 3% of US stocks

Return on assets
−57.1%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Valion Bio, Inc. has a market value of $1.0M and an enterprise value of $15.7M.

  • Revenue in the twelve months to 30 June 2026: −$156K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$18.8M, a 12019.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$14.7M.

  • Shares outstanding: 166,076.

  • Valion Bio, Inc. employs 52 people — −$3K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

VBIO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VBIOValion Bio, Inc.$1.0M2
GOVXGeoVax Labs, Inc.$985,500.0031
BBLGBone Biologics Corp.$910,000.0037
KPTIKaryopharm Therapeutics, Inc.$901,700.00—
MTNBMatinas BioPharma Holdings, Inc.$890,700.0039
SLXNSilexion Therapeutics Corp.$830,400.0028
LNAILunai Bioworks, Inc.$829,700.00—

Take a look at VBIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Valion Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about VBIO

How does Ticker Nerd's model rank VBIO?

As at 21 Nov 2026, Valion Bio, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (22 of 100).

What is the VBIO stock forecast for 2030?

No analyst covering Valion Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VBIO are extrapolating price history, which says nothing about the business.

How has VBIO stock performed over the past year?

Valion Bio, Inc. returned -98.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Valion Bio, Inc. do?

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.

Company

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

CEO Mr. J. Dean Zikria · 52 employees · United States · https://valionbio.com